{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:00:13Z","timestamp":1772002813711,"version":"3.50.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,13]]},"DOI":"10.1182\/bloodadvances.2025016131","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T19:05:51Z","timestamp":1742065551000},"page":"2336-2340","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Richards","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"4Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-488X","authenticated-orcid":false,"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, University of Maryland, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"7Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Beitinjaneh","sequence":"additional","affiliation":[{"name":"9Division of Transplantation and Cellular Therapy, University of Miami, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evguenia","family":"Bhurtel","sequence":"additional","affiliation":[{"name":"10Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara I.","family":"Cicero","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"12Department of Pharmacy, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"5Division of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"7Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Forsberg","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology, Colorado Blood Cancer Institute, Denver, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"15Division of Transplant and Cellular Therapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"16Division of Hematology\/Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[{"name":"17Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-5737","authenticated-orcid":false,"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, University of Maryland, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupama","family":"Kumar","sequence":"additional","affiliation":[{"name":"18Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Locke","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"10Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"19Division of Transplantation and Cell Therapy, Stanford Cancer Center, Palo Alto, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo D.","family":"Parrondo","sequence":"additional","affiliation":[{"name":"20Division of Hematology\/Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[{"name":"21Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Peres","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Purvey","sequence":"additional","affiliation":[{"name":"22Division of Hematology\/Oncology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"23Division of Hematology\/Oncology, Columbia Irving Medical Center, New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"24Division of Hematology and Medical Oncology, Mount Sinai Tisch Cancer Center, New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana C.","family":"Rossi","sequence":"additional","affiliation":[{"name":"24Division of Hematology and Medical Oncology, Mount Sinai Tisch Cancer Center, New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"25Division of Hematology\/Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"10Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-0781","authenticated-orcid":false,"given":"Charlotte B.","family":"Wagner","sequence":"additional","affiliation":[{"name":"25Division of Hematology\/Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh S.","family":"Zanwar","sequence":"additional","affiliation":[{"name":"26Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"19Division of Transplantation and Cell Therapy, Stanford Cancer Center, Palo Alto, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"21Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"2Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"26Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"26Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"18Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"7Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"4Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"24Division of Hematology and Medical Oncology, Mount Sinai Tisch Cancer Center, New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"9","key":"2025051308365121700_bib1","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2025051308365121700_bib2","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025051308365121700_bib3","unstructured":"Abecam\n          . Risk management plan. Bristol Myers Squibb Pharma. 2024. Accessed 28 December 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abecma."},{"key":"2025051308365121700_bib4","unstructured":"Carvykti\n          . Management plan. Janssen-Cilag International. 2024. Accessed 28 December 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/carvykti."},{"issue":"1","key":"2025051308365121700_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/19418744221128852","article-title":"Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy","volume":"13","author":"Satyanarayan","year":"2023","journal-title":"Neurohospitalist"},{"issue":"16","key":"2025051308365121700_bib6","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2025051308365121700_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-022-00657-x","article-title":"Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)","volume":"12","author":"Saw","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025051308365121700_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"2025051308365121700_bib9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"10297","key":"2025051308365121700_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2025051308365121700_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2025051308365121700_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2025051308365121700_bib13","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025051308365121700_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025051308365121700_bib15","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood-2024-201783","article-title":"Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2025051308365121700_bib16","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"28 2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025051308365121700_bib17","doi-asserted-by":"crossref","first-page":"477.e1","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed CAR-T therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"20","key":"2025051308365121700_bib18","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"2025051308365121700_bib19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2025051308365121700_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-024-01129-0","article-title":"Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel","volume":"14","author":"Banerjee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025051308365121700_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2025051308365121700_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2025051308365121700_bib23","doi-asserted-by":"crossref","first-page":"1433075","DOI":"10.3389\/fimmu.2024.1433075","article-title":"Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"2025051308365121700_bib24","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","article-title":"Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2025051308365121700_bib25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/mdc3.13942","article-title":"Parkinson's disease and driving fitness: a systematic review of the existing guidelines","volume":"11","author":"Stamatelos","year":"2024","journal-title":"Mov Disord Clin Pract"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2336\/2373354\/blooda_adv-2025-016131-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2336\/2373354\/blooda_adv-2025-016131-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T12:37:09Z","timestamp":1747139829000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/9\/2336\/536086\/Universal-driving-restrictions-beyond-4-weeks"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016131","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}